SURVODUTIDE 10mg

SURVODUTIDE 10mg
£200.00

(NOT FOR HUMAN CONSUMPTION RESEARCH USE ONLY) 

Survodutide (BI 456906)

is an investigational synthetic peptide that acts as a dual agonist for both the GLP-1(glucagon-like peptide-1) and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma, it is currently being studied for its potent effects on obesity and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as fatty liver disease. 

 

Dual Mechanism of Action 

Unlike standard GLP-1 mono-agonists like semaglutide (Wegovy), survodutide uses a "dual-action" approach to target metabolism: 

  • GLP-1 Receptor Agonism: Mimics the gut hormone to suppress appetite, increase feelings of fullness, and slow gastric emptying.
  • Glucagon Receptor Agonism: Directly targets the liver to increase energy expenditure and promote the breakdown of stored fat. This component is particularly effective at reducing hepatic fat content and liver scarring (fibrosis). 

 

Clinical Results and Efficacy

Survodutide has demonstrated record-setting results in early-to-mid-stage trials:

  • Weight Loss: In Phase 2 trials, participants achieved an average weight loss of up to 18.7% after 46 weeks, with many losing more than 20% of their body weight.
  • Liver Health (MASH): Phase 2 studies showed that 83% of adults achieved significant improvement in MASH without worsening of liver scarring, leading to "Breakthrough Therapy" status from the FDA in 2024.
  • Cardiovascular Safety: Ongoing trials like SYNCHRONIZE-CVOT are investigating its impact on heart failure and major cardiovascular events in patients with obesity. 

 

Regulatory Status and Availability

As of January 2026, survodutide is not FDA-approved for general medical use. 

  • Current Status: It is in Phase 3 registrational trials(SYNCHRONIZE program), which are expected to wrap up in the first half of 2026.
  • Expected Availability: If clinical trials are successful, a formal application for approval is expected in late 2026 or 2027.
  • Banned Substance: It is prohibited at all times in professional sports by the World Anti-Doping Agency (WADA). 

 

Common Side Effects

Most reported side effects are gastrointestinal and occur primarily during the initial dose-escalation phase: 

  • Gastrointestinal: Nausea (reported by ~66% of users in some trials), vomiting, diarrhea, and constipation.